

ASX Market Announcement

Back-to-back Studies Validate geneType Breast Cancer Risk Test

Melbourne, Australia, 13 March 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment Test in the peer-reviewed journal *Cancer Prevention Research*.

Highlights:

- 2nd published peer reviewed paper in the last month supporting the use of geneType, on the back of the ASX release dated February 9, 2023.
- Utilised a prospective cohort of more than 200,000 women from the UK Biobank.
- geneType Breast Cancer Risk Assessment Test demonstrated improved performance compared to a gold-standard model (BCRAT) over a 5-year period.
- The study showed that geneType not only put more women into an increased risk category but also demonstrated women in this category developed breast cancer at a higher incidence.

The paper entitled: [Validation of an abridged breast cancer risk prediction model for the general population](#), reports results from an extensive study undertaken by the GTG Scientific Team in collaboration with Professor John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne.

This study is the third paper accepted for publication in the last six months that highlights the utility of the geneType Breast Cancer Risk Assessment Test as powerful risk stratification tool available to the general population. GeneType improved discrimination and risk categorization when compared to one of the most well-known models, the Breast Cancer Risk Assessment Tool (BCRAT). Over a five-year period, at-risk women classified $\geq 3\%$ 5-year risk by geneType had a 1.829 times increased incidence of breast cancer compared to the general population, which was higher than the 1.413 times increased incidence for women classified $\geq 3\%$ by BCRAT.

Dr Erika Spaeth, GTG’s Director of Clinical & Medical Affairs, also lead author on the paper, noted “This publication highlights the potential utility of a risk stratification tool able to be used on the general population. There are a significant number of women that are identified as *at-increased risk* by geneType and these same women ‘fly under the radar’ if traditional clinical models are used”.

GTG’s CEO, Simon Morriss said, “This is *another* key milestone for the company highlighting our commitment to clinical and scientific validation of the geneType platform. The publication of this study in combination with the Nurses’ Health Study, provides considerable evidence of utility for our discussions with US Payers and, importantly, in gaining additional traction to initiate a pilot study with one or more of these Payers”.

-END-

Authorised for release by the board of directors of Genetic Technologies Limited.

Enquiries

Investor Relations

Adrian Mulcahy

Automic Markets

M: +61 438 630 411

E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com

Forward Looking Statements

This announcement may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.